文献速递肝病

随机临床试验:奥替普拉(一种肝X受体α抑制性二硫代硫酮)治疗非酒精性脂肪性肝病的疗效与安全性

Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2017-02-22

本研究为多中心、双盲、安慰剂对照的II期研究,纳入肝脂肪含量>20%且转氨酶升高的非酒精性脂肪性肝病患者,随机分为安慰剂组(n=22)、奥替普拉30 mg组(n=22)和60 mg组(n=24),每日两次治疗24周。主要终点为磁共振波谱测定的肝脂肪含量变化。结果显示高剂量组肝脂肪含量较安慰剂组显著降低,不良事件发生率组间相当。

要点

  • 高剂量奥替普拉组肝脂肪绝对变化为-13.9±10.7%,安慰剂组为-3.2±11.1%(P<0.01)。
  • 高剂量组肝脂肪百分比降低-34.6±29.4%,安慰剂组为-0.6±62.9%(P=0.046)。
  • 不良事件发生率组间相当,胰岛素抵抗、肝酶、血脂和细胞因子绝对变化组间无显著差异。

核心结论

  • 24周奥替普拉治疗显著降低了非酒精性脂肪性肝病患者的肝脂肪含量。

研究设计与样本

  • 多中心、双盲、安慰剂对照的II期研究;纳入肝脂肪含量>20%且转氨酶升高的非酒精性脂肪性肝病患者,随机分为安慰剂组(n=22)、奥替普拉30 mg组(n=22)和奥替普拉60 mg组(n=24),每日两次,治疗24周。
  • 主要终点为基线至24周磁共振波谱测定的肝脂肪含量变化。

主要发现

  • 肝脂肪含量绝对变化:安慰剂组-3.2±11.1%,低剂量组-7.7±7.0%(P=0.13),高剂量组-13.9±10.7%(P<0.01)。
  • 肝脂肪含量百分比降低:高剂量组-34.6±29.4% vs 安慰剂组-0.6±62.9%(P=0.046)。
  • 体重指数变化:高剂量组-1.0±0.9% vs 安慰剂组-0.5±1.4%(P=0.04)。
  • 胰岛素抵抗、肝酶、血脂和细胞因子的绝对变化组间无显著差异。
  • 不良事件发生率组间相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oltipraz is a synthetic dithiolethione with an antisteatotic effect by inhibiting the activity of liver X receptor alpha (LXR-α). Recent studies demonstrated the disruptive role of oltipraz on LXR-α-dependent lipogenesis in hepatocytes and a high-fat diet mouse model. AIM: To evaluate the efficacy and safety of oltipraz for reducing liver fat in subjects with non-alcoholic fatty liver disease (NAFLD). METHODS: We performed a multicentre, double-blind, placebo-controlled, phase II study. Subjects with a liver fat >20% and hypertransaminasemia were randomised to the three groups: placebo (n = 22), 30 mg of oltipraz (n = 22) or 60 mg of oltipraz (n = 24) twice daily for 24 weeks. Changes in the liver fat from baseline to 24 weeks quantified using magnetic resonance spectroscopy were the primary outcome. RESULTS: Compared with the placebo group (-3.2 ± 11.1%), absolute changes in the liver fat content increased in a dose-dependent manner: -7.7 ± 7.0% and -13.9 ± 10.7% for the low-dose and high-dose groups (P = 0.13 and P < 0.01). Per cent reduction in the liver fat content was also significantly greater in the high-dose group than in the placebo group (-34.6 ± 29.4% vs. -0.6 ± 62.9%, P = 0.046). Body mass indices (-1.0 ± 0.9% vs. -0.5 ± 1.4%, P = 0.04) significantly decreased in the high-dose group compared to the placebo group. However, absolute changes in insulin resistance, liver enzymes, lipids and cytokines were not significantly different among groups. The incidence of adverse events was comparable among groups. CONCLUSIONS: Twenty-four-week oltipraz treatment significantly reduced the liver fat content in patients with NAFLD. Clinicaltrials.gov (NCT01373554).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kim W, Kim BG, Lee JS, et al. Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017. PMID: 28225186. doi:10.1111/apt.13981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。